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Nephrogenic systemic fibrosis is not
exclusively associated with gadodiamide
The subject of nephrogenic systemic
fibrosis (NSF), first addressed in the
radiological community in this journal
a few months ago [1], is a fast-moving
topic with new details arising
almost every day.
NSF is a rare, debilitating, and
sometimes fatal condition that only
occurs in patients with severe renal
impairment. It is characterized by the
formation of connective tissue in the
skin, which becomes thickened,
coarse, and hard, sometimes leading to
contractures and joint immobility.
NSF has been associated with use of
certain gadolinium (Gd)-containing
magnetic resonance imaging contrast
agents in patients with severe renal
impairment [2, 3]. Since its recogni-
tion in 1997 by Dr. Sean E. Cowper, a
dermatopathologist of Yale University
[2], more than 215 cases have been
recorded [4]. Recent reports byGrobner
[5] and Marckmann et al. [7] were
among the first to suggest a linkwith the
Gd-containing contrast agent
gadodiamide (Omniscan®, Gd-DTPA-
BMA, GE Healthcare, Buckinghamshire,
UK).
Subsequent to these reports, the
United States Food and Drug Admin-
istration (FDA) issued a public health
advisory in June 2006 recommending
that Gd-containing contrast agents be
used only if clearly necessary in
patients with advanced kidney failure
and that prompt dialysis is instituted in
patients with advanced kidney failure
who receive Gd-containing contrast
agents [8]. In January of 2007, this
was followed by an announcement of
the pharmacovigilance working party
of the European Medicines Agency
(EMEA) who decided that it is con-
traindicated to use gadodiamide in
patients with a glomerular filtration
rate (GFR) below 30 ml/min, on
dialysis, and patients who have un-
dergone liver transplantation. Due to
immature kidney function in neonates
and infants up to one of age, gado-
diamide should only be used in these
patients after careful consideration [9].
At present, there is no established
treatment for NSF although a number
of therapies have been used with
varying success. For a more detailed
description of the clinical manifesta-
tions of NSF and the role of
gadodiamide, we refer the Web site of
the InternationalCenter forNephrogenic
Fibrosing Dermopathy Research [3]
and the previous editorial on this subject
by Thomsen [1].
Although the exact mechanism by
which NSF develops remains elusive,
recent publications have shed further
light on the pathogenesis of NSF.
Grobner found that patients with renal
disease who were exposed to gado-
diamide and did develop NSF were
acidotic at the time of imaging, while
those that did not develop NSF were
not acidotic [5]. In a forthcoming
publication on NSF in 1816 patients
undergoing hemodialysis, Collidge
et al. found a positive association
between the cumulative dose of
gadodiamide and the development of
NSF. Patients with nephrogenic sys-
temic fibrosis received a higher me-
dian cumulative dose of Gadodiamide
(0.39 mmol/kg v 0.23 mmol/kg,
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ium-enhanced magnetic resonance imaging than their non-
affected, gadolinium-exposed counterparts [6]. Further-
more, as the release of free Gd3+ through a process of
transmetallation in patients with reduced elimination of
Gd-containing contrast agents via the kidneys is considered
to be a possible trigger for NSF, the stability of the Gd–
chelate complexes is an important factor in the overall risk
assessment across the various contrast agents. Based on
their chemical structures, Gd-containing contrast agents
may be divided into two groups: linear (open-chain) chelates
and macrocyclic chelates. A further subdivision is made
between ionic and nonionic linear chelates [10]. Nonionic
linear chelates such as gadodiamide display clearly lower
stability values than ionic linear chelates and are character-
ized by a comparably high concentration of excess free
ligand in the formulation [10]. The ionic linear chelates such
as Gd–diethylenetriamine penta-acetic acid (DTPA) are
characterized by a much higher complex stability. Macro-
cyclic chelates differ significantly from linear chelates
regarding the kinetics of complexation and decomplexation.
Significant activation energy is necessary to both generate
and dissociate the Gd complexes, also resulting in high
complex stability [10].
Two very recent publications confirm the biological
relevance of the difference between macrocyclic and ionic
linear vs nonionic linear chelates. Boyd et al. [11] have
now convincingly demonstrated the presence of Gd in
areas of calcium phosphate deposition in blood vessels in a
skin biopsy obtained from a patient with clinical features
consistent with NSF after administration of gadodiamide.
These results were corroborated in a report by High et al.
[4] who studied tissue from seven patients with clinical and
histopathological diagnosis of NSF after gadodiamide
administration. Gadolinium was detected in the histolog-
ical specimens of four of these seven patients. In all cases,
the Gd particles appeared to be intracellular, possibly in the
lysosomes [4].
Although the overwhelming majority of known NSF
cases at this point represent patients who have been given
gadodiamide, the present update was motivated by the fact
that it has now become clear that other Gd-containing
contrast agents are also associated with NSF. In a recent
editorial in Radiology, Kuo et al. [12] report on the 57 cases
of NSF reported to the FDA. Forty-three cases of NSF were
associated with gadodiamide, six cases with gadopentetate
dimeglumine (Magnevist®; Bayer Schering Pharma AG,
Berlin, Germany), two with gadoversetamide [Opti-
MARK®, Mallinckrodt, St. Louis, MO, USA (presently
not available in Europe)], and three with both gadodiamide
and gadoversetamide. In three cases, the associated Gd-
based contrast agent was not established [12]. In a series of
13 biopsy-proven patients with NSF, Sadowski et al. [13]
also report on a case associated with both gadodiamide and
gadobenate dimeglumine (MultiHance®, Bracco Diagnos-
tics, Milan, Italy), given 1 week apart.
On the basis of spontaneous reporting of adverse drug
reactions, a total of 120 cases of NSF in association with
the administration of Omniscan® were reported by GE
Healthcare as of March 2007 [14]. A total of 42 reports of
NSF in association with gadopentetate dimeglumine have
been reported to Bayer Schering Pharma AG from
worldwide sources as of March 23, 2007. Twenty-one of
these cases were reported by a single center [15]. Onset of
NSF symptoms in all available reports dates back up to
several years. The time span between administration of MR
contrast medium and occurrence of symptoms ranges
between several days and several years. Of the total of 42
cases, 16 were assessed as possibly related, 3 were assessed
as unlikely related, and 23 were assessed as unclassifiable,
meaning that the information provided was not sufficient to
verify the diagnosis of NSF by deep skin biopsy and
histopathology and/or to link the cases exclusively to the
administration of gadopentetate dimeglumine.
At present, there are no known cases of NSF associated
with administration of other Gd-containing contrast agents
on the market in Europe: gadobutrol (Gadovist® Bayer
Schering Pharma AG), gadofosveset trisodium (Vasovist®,
Bayer Schering Pharma AG), gadoxetic acid (Primovist®,
Bayer Schering Pharma AG), gadoteridol (ProHance®, Bracco
Diagnostics), and gadoterate meglumine (Dotarem®, Guerbet
S.A., Aulnay-sur-Bois, France).
Despite the fact that, at present, not all Gd-based contrast
agents have been associated with NSF, it is paramount that
these agents be used with caution in patients with renal
insufficiency, especially considering the fact that the
pathogenesis has not definitively been established. Reflect-
ing these concerns, the Committee for Medicinal Products
for Human Use of the EMEA has requested the marketing
authorization holders of MR contrast agents to introduce a
warning in the summary of product characteristics
(“package insert”) about the occurrence of NSF in patients
with severe renal impairment.
How do these recent findings influence clinical practice?
Based on the approach by Kuo et al. [12], published in the
March 2007 issue ofRadiology, we recommend the following
approach for patients with stage 4 or 5 chronic kidney disease
(i.e., patients on peritoneal dialysis or hemodialysis) or
patients with a GFR of less than 30 ml min−1 1.73 m−2:
1. In consultation with the ordering physician, we
consider ultrasound, CT, and non-contrast-enhanced
MR angiography as alternative imaging modalities
2. We do not recommend administering gadodiamide to a
patient with any history of renal disease. We only
administer Gd-based MR contrast agents to a patient
with renal failure if the patient subsequently undergoes
dialysis. If administration of a Gd-based MR contrast
agent is deemed necessary, we consider using the
lowest dose needed to reliably provide the diagnostic
information being clinically sought. If there is a
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diagnosis or clinical suspicion of NSF in the patient,
we discourage exposure to any Gd chelates.
3. For patients maintained with hemodialysis, we ensure
hemodialysis treatment as soon as possible, ideally
within 3 h after the administration of the Gd-containing
contrast agent. A second dialysis session within 24 h
can also be performed if it is clinically safe to do so.
For patients undergoing peritoneal dialysis, we ensure
that patients have no periods with a dry abdomen (i.e.,
peritoneal cavity contains no dialysate), and we
perform more frequent manual exchanges or additional
automated peritoneal dialysis cycles for at least 48 h
after administration.
At this time, the relationship between NSF and Gd
chelates remains unclear. Further studies are now underway
at the Centers for Disease Control Prevention, the FDA,
and in the medical regulatory agencies of the European
Union. If a patient with NSF is encountered, the following
should be done [12]:
1. A history of administration of a Gd-based MR contrast
agent in the weeks or months preceding the initial
diagnosis should be ascertained. In addition, the date of
administration, the dose and brand of the contrast agent
administered, as well as the date of onset or diagnosis
of NSF should be noted.
2. The event should be reported to the EMEA (http://
www.emea.europa.eu) and FDA online through the
MedWatch reporting program (http://www.fda.gov/
medwatch/) or by phone (1-800-FDA-1088) or appro-
priate non-E.U./non-US regulatory agencies.
3. The case should be reported to the NSF registry at Yale
University (http://www.icnfdr.org) and to the European
Society of Urogenital Radiology (http://www.esur.org).
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